Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Drug companies told to do more to tackle 'superbug' crisis

share with twitter share with LinkedIn share with facebook
share via e-mail
01/23/2018 | 04:41pm CET
FILE PHOTO: A sample bottle containing E.coli bacteria is seen at the Health Protection Agency in London

Drugmakers' response to the threat posed by "superbugs" remains patchy even after years of warnings, according to the first analysis of individual companies' efforts to tackle the antibiotic resistance crisis.

The rise of drug-resistant bacteria is a growing threat to modern medicine with the emergence of infections resistant to even last-resort antibiotics - a situation made worse in recent years by overuse of antibiotics and cutbacks in drug research.

New analysis by the non-profit Access to Medicine Foundation (AMF), published on Tuesday, found that GlaxoSmithKline (>> GlaxoSmithKline) and Johnson & Johnson (>> Johnson & Johnson) were doing more than most among large research-based pharmaceutical companies to tackle the problem, while Mylan (>> Mylan NV) led the way among generic drugmakers and Entasis was top among biotechs.

Overall, GSK led the field with 55 antimicrobial pipeline projects, including 13 vaccines.

But action taken by such companies is only the start of what could be done to address the problem, which former Goldman Sachs chief economist Jim O'Neill in 2014 estimated could cause 10 million deaths a year worldwide by 2050.

"The whole of modern medicine depends on being able to control and treat infections," said Jeremy Farrar, director of the Wellcome Trust charity. "Perhaps the most exciting area of medicine at the moment, immunotherapies for cancer, is impossible unless you can control infection."

While more experimental antibiotics are now moving through development than a few years ago, the number is still down on the 1980s and 1990s. And a lot more work needs to be done to ensure appropriate use of medicines - both new ones and the thousands of tonnes of older pills churned out each year by generic companies.

"There's definitely more that all companies can do," said Jayasree Iyer, executive director of AMF, which published the analysis at the World Economic Forum annual meeting in Davos.

"We need to strengthen the research and development pipeline - and when new products reach the market we need to ensure that they are used in a conservative way, so that misuse and overuse is limited."

There are now 28 experimental antibiotics in late-stage development against critical pathogens but only two of these are supported by plans to ensure they can be both made accessible and used wisely if they reach the market.

The AMF said four companies - GSK, Shionogi (>> Shionogi & Co Ltd), Pfizer (>> Pfizer) and Novartis (>> Novartis) - had taken steps to separate sales representatives' bonuses from the volume of antibiotics sold, but much more needed to be done across the industry to counter overuse.

Another under-recognised problem is the pollution caused by mass production of antibiotics, due to lax oversight of wastewater run-off.

In India's Hyderabad region, for example, the presence of hundreds of drug factories and inadequate water treatment has left lakes and rivers laced with antibiotics, making the area a giant Petri dish for anti-microbial resistance.

The AMF urged multinational drugmakers to do more to ensure that their suppliers of bulk antibiotic ingredients were complying with rigorous wastewater standards.

(Editing by Susan Fenton and Mark Potter)

By Ben Hirschler

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
01/23 Drug companies told to do more to tackle 'superbug' crisis
01/23 ADVANCED ACCELERATOR APPLICATION : s Announces Completion of $3.9 Billion Novart..
01/22 NOVARTIS : reports erenumab met all primary and secondary endpoints in unique Ph..
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 BIOCON : stock surges 6% on collaboration with Sandoz
01/22 BIOCON : ties up with Swiss pharma firm for biosimilars
01/22 NOVARTIS : completes tender offer for Advanced Accelerator Applications S.A. and..
01/22 NOVARTIS : completes tender offer for Advanced Accelerator Applications S.A. and..
01/21 BIOCON : stock surges 6% on collaboration with Sandoz
More news
News from SeekingAlpha
01/23 Ionis Pharmaceuticals Is Poised To Disrupt Biotech
01/23 Notable earnings before Wednesday?s open
01/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 22, 2018
01/22 Biotech Forum Daily Digest For January 21st
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 771 M
Net income 2017 7 500 M
Debt 2017 17 632 M
Yield 2017 3,27%
P/E ratio 2017 25,02
P/E ratio 2018 21,80
EV / Sales 2017 4,97x
EV / Sales 2018 4,76x
Capitalization 227 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 88,5 $
Spread / Average Target 2,0%
EPS Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS1.29%226 840
JOHNSON & JOHNSON5.47%397 981
PFIZER1.99%220 129
ROCHE HOLDING LTD.-4.34%211 542
AMGEN8.84%139 614